Latest antiretroviral therapy Stories
In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.
A multidisciplinary team of researchers from UCLA and India has found that a new type of intervention program, in which lay women in the rural Indian province of Andra Pradesh were trained as social health activists to assist women who have HIV/AIDS, significantly improved patients' adherence to antiretroviral therapy and boosted their immune-cell counts and nutrition levels.
People with HIV are more likely to keep their scheduled medical appointments — and their disease under control — if they feel their physician listens, explains things clearly and knows them as a person, not just a "case," new Johns Hopkins research suggests.
Antiretroviral therapy does not affect resting energy expenditure among women with HIV.
In South Africa, people with HIV who start treatment with anti-AIDS drugs (antiretroviral therapy) have life expectancies around 80% of that of the general population provided that they start treatment before their CD4 count drops below 200 (cells per microliter).
HIV-positive patients have a higher incidence of non-melanoma skin cancers.
Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date — and who have higher counts of CD4+ T-cells at the initiation of therapy — demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later.
In South Africa, HIV-infected men who are receiving treatment with anti-HIV drugs (antiretroviral therapy) are almost a third more likely to die than HIV-positive women who are receiving similar treatment: however, these differences are likely to be due to gender differences in death rates in the general population rather than related to HIV.
Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.